A 42-year-old man is brought to the emergency department due to progressive fatigue, easy bruising, and bleeding gums for the past week. His temperature is 37.8°C (100.0°F), blood pressure is 110/70 mm Hg, and pulse is 98/min. Physical examination shows diffuse petechiae over the extremities and oozing from the gingiva.
Laboratory studies show:
| Test | Result | Reference Range |
|---|---|---|
| Hemoglobin | 8.2 g/dL | 13.5-17.5 g/dL |
| Leukocyte count | 18,000/mm³ | 4,500-11,000/mm³ |
| Platelet count | 24,000/mm³ | 150,000-400,000/mm³ |
| Prothrombin time | 18 sec | 11-15 sec |
| Activated partial thromboplastin time | 45 sec | 25-40 sec |
| Fibrinogen | 90 mg/dL | 150-400 mg/dL |
A peripheral blood smear reveals numerous atypical promyelocytes with folded nuclei and multiple needle-like intracytoplasmic inclusions (Auer rods).
Arrange the following management steps in the most appropriate chronological order.
- 1Initiate all-trans retinoic acid (ATRA) immediately
- 2Perform bone marrow aspiration and biopsy for cytogenetic confirmation
- 3Administer induction chemotherapy (e.g., arsenic trioxide or anthracycline)
- 4Monitor for the development of differentiation syndrome
Answer
The correct sequence is to immediately initiate ATRA, then perform a bone marrow biopsy for cytogenetic confirmation, followed by induction chemotherapy, and finally monitor for differentiation syndrome over the coming weeks.
The correct sequence for managing suspected acute promyelocytic leukemia (APL) requires treating the immediate life-threatening complication (DIC) prior to definitive diagnosis. ATRA promotes differentiation of the malignant cells and resolves the coagulopathy. Therefore, ATRA is given first. Once started, a bone marrow biopsy is obtained for definitive cytogenetic diagnosis (t(15;17)). Following confirmation, definitive induction chemotherapy (e.g., arsenic trioxide) is administered. Finally, because ATRA and arsenic trioxide cause massive differentiation of promyelocytes, the patient must be monitored continuously for differentiation syndrome, which typically presents days to weeks later.
Step-by-Step Solution
Key Concept
In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be initiated immediately based on clinical and peripheral smear findings to treat life-threatening DIC, before obtaining a confirmatory bone marrow biopsy.